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Imprinted genes, which are expressed from a single parental allele in response to epigenetic marks ﬁrst
established in the germline, function in a myriad of processes to regulate mammalian development.
Recent work suggests that imprinted genes may regulate the signalling function of the placenta by
modulating the size of the endocrine compartment. Here we provide in vivo evidence that this hy-
pothesis is well founded. Elevated expression of the imprinted Pleckstrin homology-like domain, family a,
member 2 (Phlda2) gene drives a reduction of the spongiotrophoblast endocrine compartment, dimin-
ished placental glycogen and asymmetric foetal growth restriction. Using both loss-of-function and gain-
in-expression mouse models, here we further show that Phlda2 exclusively modulates the spongio-
trophoblast compartment of the placenta without signiﬁcantly altering the composition of the tropho-
blast giant cell endocrine lineages that share a common progenitor with this lineage. Additionally, we
show that Phlda2 loss-of-function placentae contain nearly three times more placental glycogen than
non-transgenic placentae. Remarkably, relative to a fully wild type scenario, wild type placentae also
accumulate excessive glycogen. While loss-of-function of Phlda2 increased both placental weight and
placental glycogen, the weight of both mutant and non-transgenic fetuses was lower than that found in a
fully wild type scenario indicating that excessive glycogen accumulation comes at the cost of foetal
growth. This work ﬁrstly highlights a novel signalling function for the spongiotrophoblast in stimulating
the global accumulation of placental glycogen. Furthermore, this work suggests that Phlda2 manipulates
the placenta's demands for maternal resources, a process that must be tightly regulated by epigenetic
marks to ensure optimal foetal growth.
Crown Copyright & 2015 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Genomic imprinting is an epigenetic phenomenon which
drives the preferential expression of certain genes from one par-
ental allele (John and Surani, 1996). The ﬁnding that some pater-
nally silenced genes restrain foetal growth while some maternally
silenced genes are growth promoting led to the suggestion that
imprinting may have evolved in response to the different energetic
contributions that male and female mammals make to their off-
spring (Moore and Haig, 1991) and the effectively antagonistic
selective pressure acting on the mother–offspring relationship
(Moore, 2011). However, another conﬂict exists in mammals be-
cause maternal resources are utilised by both the growing foetus
and the developing extra-embryonic tissues. In some mammals
these supporting tissues can consume more than half the maternal
resources allocated to a pregnancy (Fowden, 1997; Carter, 2000)evier Inc. This is an open access arintroducing the potential for competition between their energetic
requirements and that of the growing foetus.
In mice, a signiﬁcant number of imprinted genes functionally
converge to regulate placental growth and development (Tunster
et al., 2013). The mature mouse placenta supports foetal growth
from approximately embryonic day (E) 9.5 until birth and is or-
ganised into the histologically distinct labyrinth zone, junctional
zone and maternal decidua interspersed with trophoblast giant
cells (TGCs) lining the maternal tissues and vasculature at speciﬁc
sites (Rai and Cross, 2014). While the function of the labyrinth in
placental transport is well established, the function of the spon-
giotrophoblast and the glycogen cell lineages, which reside within
the junctional zone, has yet to be fully determined experimentally.
Placental glycogen, which accumulates in the glycogen cells of the
junctional zone from mid-gestation, may provide a store of easily
mobilisable energy late in gestation to support the ﬁnal stages of
foetal growth (Coan et al., 2006) supported by numerous mouse
models in which limited glycogen stores are associated with foetal
growth restriction (Lefebvre, 2012). The function of theticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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placental lactogens (Prls) and pregnancy-speciﬁc glycoproteins
(Psgs) are expressed from this lineage some of which have been
shown to act on the mother to induce the physiological changes
required for a successful pregnancy (Samaan et al., 1968; Bhatta-
charyya et al., 2002; Muller et al., 1999; Kammerer and Zimmer-
mann, 2010; Wu et al., 2008). While this lineage is required for
foetal viability (Guillemot et al., 1994; Ono et al., 2006), fetuses can
survive to term with very little spongiotrophoblast (Oh-McGinnis
et al., 2011). A reduced spongiotrophoblast has been linked to
foetal growth restriction in several studies (Oh-McGinnis et al.,
2011; Hitz et al., 2005; Zheng-Fischhofer et al., 2007; Withington
et al., 2006; Tunster et al., 2010) while an expanded spongio-
trophoblast may drive delayed parturition associated with foetal
and maternal death (Denda et al., 2011). Loss of function of several
maternally expressed imprinted genes results in an expansion of
the spongiotrophoblast lineage (John and Hemberger, 2012), most
recently Sirh7/Ldoc1 (Naruse et al., 2014), suggesting that the pa-
ternal genome has selectively silenced genes that limit spongio-
trophoblast-speciﬁc functions. However, while there are a number
of mouse mutants in which alterations in the spongiotrophoblast
lineage have been reported, these defects commonly occur
alongside alterations in additional placental lineages. In particular,
the glycogen cell lineage and four of the six distinct TGC lineages
which share a common progenitor with the spongiotrophoblast
(Rai and Cross, 2014; Hu and Cross, 2010; Simmons et al., 2007;
Gasperowicz et al., 2013) confounding their functional assessment.
Pleckstrin homology-like domain family A member 2 (Phlda2) is a
maternally expressed gene that maps to the imprinted domain on
mouse distal chromosome 7, which encodes a PH domain-only
protein (Frank et al., 1999; Qian et al., 1997). Prior to the formation
of the mature mouse placenta, Phlda2 is expressed most strongly
in the ectoplacental cone and the visceral endoderm of the yolk
sac (Frank et al., 1999; Dunwoodie and Beddington, 2002; Takao
et al., 2012). The ectoplacental cone contains the trophoblast spe-
ciﬁc protein alpha (Tpbpa)-positive progenitors that give rise to the
spongiotrophoblast, the glycogen cells and four of the six TGC
subtypes of the mature placenta (Rai and Cross, 2014; Simmons
et al., 2007, 2008; Gasperowicz et al., 2013). Loss-of-function of
Phlda2 results in an enlarged placenta with an expanded junc-
tional zone and more placental glycogen but without foetal over-
growth (Frank et al., 2002). Elevated expression, at two-fold the
endogenous level, results in placental stunting, a loss of the
spongiotrophoblast lineage and reduced placental glycogen accu-
mulation but without an alteration in the representation of the
glycogen cell lineage or the parietal trophoblast giant cells which
line the maternal decidua (Tunster et al., 2010; Salas et al., 2004).
Additionally, elevated Phlda2 drives a late, asymmetric foetal
growth restriction (Tunster et al., 2014). Taken together, these data
suggested that Phlda2 acts indirectly to restrain foetal growth by
limiting the expansion of the spongiotrophoblast lineage, which is
required to stimulate glycogen accumulation. However, the effects
of elevated Phlda2 gene dosage on all the TGCs lineages has not
been reported. Moreover, a characterisation of the placental
lineages in the context of loss-of-function has not been performed.
To further investigate the role of Phlda2 in regulating the placental
endocrine lineages, glycogen accumulation and foetal growth, we
performed an examination of the placental lineages in the different
Phlda2 gene dosage mouse models and biochemically quantiﬁed
placental glycogen at different stages of development in response to
loss-of-function of Phlda2. Remarkably, in addition to the anticipated
over accumulation of placental glycogen in response to loss-of-
function of Phlda2, we noted a similar phenotypes in non-transgenic
placenta sharing the uterine environment. Rather than supporting
enhanced foetal growth, these stores came to the detriment of foetal
growth identifying a novel role for Phlda2 in regulating maternalresource allocation between the placenta and the foetus.2. Materials and methods
2.1. Mouse strains and genotyping
Animal studies and breeding were approved by the Universities
of Cardiff Ethical Committee and performed under a UK Home Of-
ﬁce project license (RMJ). All mice were housed under standard
conditions throughout the study on a 12 h light–dark cycle with
lights coming on at 06.00 h with a temperature range of 21 °C72
with free access to water (tap water) and standard chow. The Phlda2
targeted allele (Frank et al., 2002) was crossed into the 129S2/SvHsd
(Harlan, 129) strain background for þ8 generations. The single copy
Phlda2 transgenic line Phlda2þ /þBACx1 (Tunster et al., 2014) was
maintained on the 129 background by paternal transmission. Phlda2
deﬁcient fetuses were generated by crossing Phlda2þ / females
with wild type males. Phlda2þ / females were crossed with
Phlda2þ /þBACx1 males to generate four genotypes: Phlda2þ /þ (non-
transgenic; 1X), Phlda2 /þ (maternal KO; 0X), Phlda2þ /þBACx1
(single copy Phlda2 transgene; 2X) and Phlda2 /þBACx1 (single copy
transgene plus maternal KO; 1X). 129 wild type colonies were
maintained alongside the transgenic colonies. For recipient transfer
experiments, 2-cell embryos were surgically transferred into E0.5
wild type 129 recipients mated with vasectomised males.
2.2. Quantitative RNA analysis
RNA was extracted from whole placenta following careful re-
moval of membranes and umbilicus. Quantitative PCR of reverse
transcribed RNA (RT-qPCR) was performed and analysed as de-
scribed (Tunster et al., 2010; Schmittgen and Livak, 2008). RNA
was hybridised to Affymetrix Mouse Gene 2.0 ST chips. Data was
analysed essentially as described (Zhang et al., 2009) and using
Partek Genomic suite. Genes signiﬁcantly up in Phlda2 /þ ) (0X)
and signiﬁcantly down in Phlda2þ /þBACx1 (2X) E16.5 whole pla-
centa were tested for enrichment of gene ontology molecular
function and biological process using the Database for Annotation,
Visualisation and Integrated Discovery (DAVID). Microarray data
available in GEO repository accession *******.
2.3. In situ hybridisation and histological analyses
Placentas were ﬁxed overnight in phosphate-buffered 4% paraf-
ormaldehyde, parafﬁn-embedded and 6 μm sections taken through
the midline. Riboprobe preparation and in situ hybridisation were
performed as previously described (Tunster et al., 2010, 2012).
2.4. Weighing studies and biochemical determination of placental
glycogen concentration
Foetal and placental wet weights were taken at the stated time
points after a discernable plug and normalised. Genotyping data
was obtained from yolk sac DNA as previously described (Frank
et al., 2002; John et al., 2001). Glycogen was extracted from whole
placenta, and resuspended in 1 ml of H2O and assayed according
to the method of Lo et al. (1970) at a dilution of 1 in 2.
2.5. Statistical analyses
Statistical signiﬁcance (probability values) was determined
using the Student's t-Test (two tailed distribution and two sample
unequal variance) for comparisons between knockout and control
littermates. Comparisons with the fully wild type scenario were
undertaken using ANOVA with Bonferroni correction.
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3.1. Phlda2 supresses the expansion of the spongiotrophoblast
without altering the representation of the TGC lineages
A characterisation of placental lineages in response to loss of
Phlda2 function was undertaken after breeding the original lineTpbpa
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Fig. 1. Phlda2 restrains the expansion of the spongiotrophoblast lineage without signiﬁca
markers mRNA levels between E14.5 Phlda2þ /þ(non-transgenic; 1X) and Phlda2 /þ(0X
hybridisation with Prl3d (Pl1) of midline sections from E10.5 Phlda2þ /þ(1X), Phlda2 /þ(0
of midline sections E14.5 placenta with Tpbpa, Prl8a8, Prl3b1 (Pl2) and Prl2c (Plf) (scale b
of the canal and the spiral artery TGC (scale bar¼100 μm). For the RT-qPCR analysis, N¼
SEM. Statistical signiﬁcance calculated using t-test. NSP40.05, *Po0.05, **Po0.01, andcarrying a targeted deletion of Phlda2 onto a 129S2/SvHsd (129)
genetic background. Phlda2 /þ (maternal KO; 0X) placenta ex-
pressed Tpbpa, a gene expressed by both the spongiotrophoblast
and the glycogen cell lineage (Lescisin et al., 1988), at 2.20-fold
(70.26; p¼3.77104) the normal level (Fig. 1A, and Table S1).
Prl8a8, a gene expressed exclusively in spongiotrophoblast cells
(Simmons et al., 2008), was elevated by 2.10-fold (70.15;Phlda2+/+BACx1 )X2( Phlda2-/+BACx1 )X1(
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) placentae from littermates examined on the 129 genetic background. B. In situ
X), Phlda2 /þBACx1(2X) and Phlda2 /þBACx1 (1X) 129 placenta. C. In situ hybridisation
ar¼200 μm). Prl2c also shown at a higher magniﬁcation illustrating similar staining
4 placenta per genotype (2 vs 2 from 2 independent litters); error bars represent
***Po0.005.
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the junctional zone (Breier et al., 1995) was elevated by 2.31-fold
(70.51; p¼0.00551). Expression of glycogen cell markers (Gjb3/
Cx31 and Pcdh12) and traditional markers of the labyrinth was
comparable to wild type (Fig. 1A). These data were reciprocal to
our ﬁndings in the gain-in-expression Phlda2model (Tunster et al.,
2010, 2014) conﬁrming the inverse relationship between Phlda2
gene dosage and the spongiotrophoblast but not the glycogen cell
lineage. Some markers of the TGC lineages, Tle3 and Ctsq, were
expressed normally whereas Prl2c (Plf) and Prl3b1, which are ex-
pressed in both the spongiotrophoblast and TGCs, were elevated in
response to loss-of-function of Phlda2 (Fig. 1A) suggesting that
some TGC lineages may also be altered in this model. To further
reﬁne the analysis, four placental genotypes were generated from
crosses between Phlda2þ / females and males carrying a single
copy of a transgene spanning the Phlda2 locus: Phlda2þ /þ (non-
transgenic; 1X), Phlda2 /þ (maternal KO; 0X), Phlda2þ /þBACx1
(single copy Phlda2 transgene; 2X) and Phlda2 /þBACx1 (single
copy transgene plus maternal KO; 1X). In situ hybridisation per-
formed with Prl3d, an exclusive marker of the parietal TGC lineage
at E10.5 (Simmons et al., 2008), excluded any gross alterations in
this lineage (Fig. 1B). Hybridisation with Tpbpa and Prl8a8 at E14.5
further highlighted the inverse relationship between Phlda2 gene
dosage and the spongiotrophoblast with an expansion of this
lineages occurring in response to the decreasing expression of
Phlda2. Hybridisation with Prl2b1 and Prl2c, which identify thePsg17 
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Fig. 2. Phlda2 indirectly suppresses the expression of key placental hormones. A.
Phlda2 /þBACx1(2X) and Phlda2 /þBACx1(1X) 129 placentae. B. RT-qPCR comparison of P
(scale bar¼200 μm). For the RT-qPCR analysis, N¼4 placenta per genotype (2 vs 2 from
using t-test. NSP40.05, *Po0.05, **Po0.01, and ***Po0.005.canal, sinusoidal and spiral artery TGCs (Simmons et al., 2007),
was similar irrespective of Phlda2 gene dosage (Fig. 1C) indicating
that these lineages were relatively unaffected by the loss-of-
function of Phlda2. These data identiﬁed Phlda2 as a gene that acts
exclusively to constrain the expansion of the spongiotrophoblast
lineage without signiﬁcantly altering the cellular composition of
other trophoblast lineages which share a common progenitor.
3.2. Phlda2 regulates the expression of several placental hormones
The spongiotrophoblast expresses a number of Prls (Simmons
et al., 2008), genes that encode placental lactogens that act on the
mother during pregnancy to induce changes required for a suc-
cessful pregnancy (John, 2013). Several Prl members were elevated
in the Phlda2 /þ (maternal KO; 0X) placenta and reduced in the
Phlda2þ /þBACx1 (2X) placenta (Fig. 2A,Table S1). The spongio-
trophoblast is also a major source of pregnancy speciﬁc glyco-
proteins (Psgs), another large gene family important for pregnancy
(McLellan et al., 2005). RT-qPCR analysis of the most abundantly
expressed Psgs during mid gestation, Psg17, Psg18, Psg19 and Psg21
(Fig. 2B), and in situ hybridisation with Psg17 (Fig. 2C) revealed a
reciprocal relationship between Phlda2 expression and the Psgs.
In situ hybridisation (Figs. 1B, C and 2C) and RT-qPCR analyses
(Table S1) on double transgenic placenta carrying both the trans-
gene and the maternally inherited targeted Phlda2 allele (1X)
formally assigned these changes to Phlda2.E14.5 
hlda2+/+BACx1 (2X) Phlda2-/+BACx1 (1X) 
a1 Prl8a6 Prl8a9 
** 
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RT-qPCR comparison of Prls at E14.5 between Phlda2þ /þ(1X), Phlda2 /þ(0X),
sgs at E14.5. C. In situ hybridisation of midline sections E14.5 placentae with Psg17
2 independent litters); error bars represent SEM. Statistical signiﬁcance calculated
Fig. 3. Microarray analysis identiﬁes the transcriptomic signature of the spongiotrophoblast. A. Three-dimensional principle components analysis plot clustering placental
gene expression with genotypes. B. Heat map showing genes signiﬁcantly altered in relations to changes in Phlda2 gene dosage. The colour represents the expression level of
the gene. Red represents high expression, while green represents low expression. The expression levels are continuously mapped on the colour scale provided at the bottom
of the ﬁgure. Phlda2 /þ(0X) and Phlda2þ /þBACx1(2X) placenta show a reciprocal pattern of expression. C. Enrichment for placental hormones after pathways analysis of genes
signiﬁcantly UP in Phlda2 /þ (129)(0X) and signiﬁcantly DOWN in Phlda2þ /þBACx1(2X) placenta (pr0.05) presumed to originate within the spongiotrophoblast. Supplemental
Table 1 list the DAVID results and the UP DOWN annotated probe sets with a signiﬁcant differences in gene expression at PZ0.05.
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performed using an Affymetrix mouse microarray to proﬁle gene
expression on E16.5 Phlda2þ /þ (1X), Phlda2 /þ (0X) and
Phlda2þ /þBACx1 (2X) placenta (N¼3–4 of each genotype, two in-
dependent litters for each genotype). Data was initially analysed at
the genome wide level using a Bioconductor package Limma
(Linear Model for Microarray data Analysis) written in R statistical
software to identify differentially expressed genes between all
pair-wise comparisons of the groups (Fig. 3A and B). Database for
Annotation, Visualisation and Integrated Discovery (DAVID) wasused to generate molecular function and biological processes
pathway data on the unselected dataset highlighting signiﬁcant
changes in genes involved in cell cycle, cytokine–cytokine inter-
actions and sphingolipid metabolism (Table S2). Genes both sig-
niﬁcantly up in Phlda2 /þ placenta and signiﬁcantly down in
Phlda2þ /þBACx1 E16.5 whole placenta likely represent the spon-
giotrophoblast transcriptome (Fig. 3C, and Table S3). A dataset of
these UP DOWN genes was further analysed by DAVID giving a
functional annotation clustering analysis output which highlighted
cytoskeleton pathways, cell division pathways and the protein
S.J. Tunster et al. / Developmental Biology 409 (2016) 251–260256superfamily prolactin/lactogen/growth hormone cluster (Cluster
3 Enrichment Score: 4.25) (Tables S4 and S5). Within cluster
3 were a number of placental prolactins known to be expressed
within the spongiotrophoblast (Simmons et al., 2008) and secretin,
also highly expressed within the spongiotrophoblast (Knox et al.,
2011) (Table S6). This data, together with our RT-qPCR and in situ
analyses (Figs. 1 and 2), conﬁrmed Phlda2 as a major rheostat for
placental hormone gene expression.
3.3. Excessive accumulation of placental glycogen in Phlda2-deﬁ-
cient placenta
Phlda2-deﬁciency results in a transient foetal growth restric-
tion in C57BL/6 (BL6) mice (Frank et al., 2002; Salas et al., 2004).
Given the less favourable foetal:placental ratio in 129 mice0 
1 
2 
3 
4 
5 
6 
E14.5 E16.5 E18.5 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
E14.5 E16.5 E18.5 
Fe
ta
l w
ei
gh
t (
g)
 
NS 
NS 
NS 
0 
4 
8 
12 
16 
E14.5 E16.5 E18.5 
F:
P 
R
at
io
 
*** 
*** 
*** 
G
ly
co
ge
n 
(m
g/
g)
  **  *  NS 
Fig. 4. Inﬂuence of Phlda2 deﬁciency on foetal and placental weights, and glycogen accu
gestational stages. Phlda2 /þ(0X) fetuses weigh the same as their non-transgenic counte
Phlda2 /þ(0X) placenta weigh more than their non-transgenic counterparts at each tim
determination of total glycogen (mg) stored in Phlda2þ /þ and Phlda2 /þ(0X) placenta at
than non-transgenic placenta at E16.5 and E18.5. E. Milligrams (mg) of glycogen stored
Numbers of samples given in Supplemental Table S7. Error bars represent SEM. Sta
***Po0.005.(Tunster et al., 2012), we asked whether foetal overgrowth might
manifest on this genetic background. Phlda2 /þ fetuses were si-
milar in weight to their 129 non-transgenic counterparts at E14.5,
E16.5 and E18.5 (Fig. 4A). Phlda2 /þ placenta weighed more than
non-transgenic at each time point with a maximal increase of 50%
at E16.5 (p¼7.42108) (Fig. 4B). Phlda2-deﬁciency resulted in a
lower F:P ratios (Fig. 4C) particularly evident at E16.5 with a
change in ratio from 8.870.26 to 6.470.30 (73.1% of control;
p¼2.75106).
Phlda2-deﬁciency resulted in increased Periodic Acid Schiff
(PAS) staining for glycogen (Tunster et al., 2010; Frank et al., 2002).
When we biochemically determined the amount of glycogen
stored in the 129 placenta, Phlda2-deﬁciency resulted in greater
stores of placental glycogen, as anticipated, with a maximal dif-
ference in total glycogen at E16.5 of 2.3-fold (129; Fig. 4D). These0 
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into account (Fig. 4E).
3.4. Global foetal growth restriction
Given the function of Phlda2 in restraining the spongio-
trophoblast lineage and thus, indirectly, the production of pla-
cental hormones, loss-of-function of Phlda2 might promote the
accumulation of placental glycogen and potentially support the
increased growth of both the loss-of-function fetuses and their
non-transgenic counterparts sharing the intrauterine environ-
ment. The within litter comparison would not necessary exclude
this possibility. To address this, data on Phlda2-deﬁcient fetuses
and their non-transgenic littermates were compared to those from
fully wild type litters at E18.5 collected concurrently using the
parent strain. Remarkably, rather than an anticipated increase in
foetal weights, we observed a 15% reduction in weight of both
Phlda2 /þ and Phlda2þ /þ compared to fully wild type litters
(Fig. 5A). Non-transgenic placentae were similar in weight to fully
wild-type placentae (Fig. 5B). Consequently the F:P ratios for both
the Phlda2-deﬁcient scenario and the non-transgenic scenario
were both signiﬁcantly different to the fully wild-type scenario
(Fig. 5C). Remarkably, while placental glycogen stores from non-
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placenta on the 129 genetic background when placental weights are taken into accoun
Statistical signiﬁcance calculated using one way ANOVA with Bonferroni correction forper gram of placenta than the Phlda2-deﬁcient placenta, they
contained more glycogen overall than the fully wild type placenta
(Fig. 5D). Phenotypes in the non-transgenic samples sharing the
intrauterine environment with the transgenic individuals high-
lighted a global effect on the entire litter as a result of localised
loss-of-function of Phlda2.
The litters we examined were carried by dams inheriting the
targeted Phlda2 allele, albeit paternally and thus the inactive allele.
While Phlda2 is imprinted strongly in the placenta and extra-
embryonic membranes, functional imprinting is less well main-
tained in embryonic and adult tissues (Qian et al., 1997). To for-
mally exclude a haploinsufﬁciency phenotype in the dams, Phlda2-
deﬁcient embryos and their non-transgenic controls were trans-
ferred into wild-type recipient mothers. The weights of both
Phlda2 /þ (KO) and non-transgenic fetuses were signiﬁcantly
lighter when compared to fully wild-type litters (Fig. 6A).
Phlda2 /þ (KO) placental weights were signiﬁcantly increased
(Fig. 6B) and the F:P ratio was lower (Fig. 6C). Importantly, whe-
ther examined as total glycogen or as glycogen per gram of pla-
centa, the Phlda2 /þ (KO) and non-transgenic values were sig-
niﬁcantly higher than fully wild-type control values (Fig. 6D and
E). These data excluded a maternal genotype-effect and identiﬁed
a novel function for the spongiotrophoblast in promoting the
global accumulation of placental glycogen.Phlda2-/+ (0X)  
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Here we show that the imprinted Phlda2 gene acts in a lineage-
speciﬁc manner to exclusively modulate the size of the spongio-
trophoblast compartment of the mature mouse placenta. Phlda2 isE
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in regulating placental glycogen accumulation. Trophoblast lineage allocation and
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function of Phlda2, drives an inappropriate accumulation of pla-
cental glycogen both locally, in the genetically modiﬁed in-
dividuals, and also globally in individuals that were genetically
wild type. This work identiﬁes a novel signalling function for the
spongiotrophoblast. The presence of foetal growth restriction in
both the genetically modiﬁed individuals and their non-transgenic
counterparts further suggests that Phlda2 balances resource allo-
cation between the foetus and the placenta, a process that must be
precisely regulated for optimal foetal growth.
Phlda2 is the only gene to date which acts to limit the size of
the spongiotrophoblast compartment of the mouse placenta
without signiﬁcantly altering the contribution of additional pla-
cental lineages that share a common progenitor (Rai and Cross,
2014). This suggests that Phlda2 acts in placental development
after these lineage decisions are made but before Phlda2 expres-
sion subsides (Fig. 7). This unique speciﬁcity for the spongio-
trophoblast allowed us to explore the function of the spongio-
trophoblast. One key ﬁnding from this study was that an expanded
spongiotrophoblast drove the excessive accumulation of placental
glycogen both directly, within the loss-of-function placenta, and
also indirectly in the non-transgenic placenta sharing the uterine
environment. To our knowledge, this is the ﬁrst example of a gene
modiﬁcation affecting the phenotype in wild type conceptuses of
the same litter. However, very few studies make the comparison
with fully wild type data. These data suggest that the spongio-
trophoblast produces a signal that acts locally and at a distance to
stimulate glycogen accumulation. The spongiotrophoblast ex-
presses a number of placental prolactins (Simmons et al., 2008)
and pregnancy speciﬁc glycoproteins (McLellan et al., 2005).
Consequently, by changing the size of the spongiotrophoblast
compartment, Phlda2 indirectly and negatively regulates the ex-
pression of several placental hormones. Many of these placental
hormones act on the maternal system to channel nutrients to the
foetus and ensure a healthy and successful pregnancy (Samaan
et al., 1968; Bhattacharyya et al., 2002; Muller et al., 1999; Kam-
merer and Zimmermann, 2010; Wu et al., 2008). One explanation
for our ﬁndings is that an increased signal (Phlda2 loss-of-func-
tion) leads to increased nutrient availability potentially explaining
increased placental glycogen in both genotypes. However, we
observed foetal growth restriction of both the Phlda2 KO fetuses
and their non-transgenic, genetically wild-type littermates. We
could discount a haploinsufﬁciency phenotype in the dams, which
carry the paternal targeted allele, because embryos transferred
into wild-type recipients also displayed both foetal growth re-
striction and excessive placental glycogen of both genotypes
(Fig. 6). Another explanation is that the defect lies at the level of
foetal uptake of glucose or the ability to transport it across the
placenta to the foetus such that placental glycogen accumulates
because it is not utilised. A third explanation is that the spongio-
trophoblast produces a signal demanding nutrients to support
placental growth. When the signal is too high, as in the Phlda2
loss-of-function model, it outcompetes the demand signal from
the foetus resulting in the diversion of maternal resources away
from supporting foetal growth and towards supporting placental
growth. This latter explanation is plausible as the placenta is a
highly metabolic organ consuming maternal energy in order to
support the active transport of nutrients to the foetus and also the
production and secretion of vast quantities of placental hormones
(John, 2013). In mammals, more than half of the total uterine
glucose and oxygen uptake is channelled to the uteroplacental
tissues (Fowden, 1997; Carter, 2000). A larger placenta, observed
in the Phlda2 loss-of-function model, would require a greater
proportion of maternal resources that might occur to the detri-
ment of foetal growth. While further work is required to de-
termine the precise mechanism driving foetal growth restriction inthis model, this study has demonstrated that a precisely regulated
dose of Phlda2 is essential for optimal foetal growth with both
loss-of-function and gain-in-expression driving foetal growth re-
striction in mice.
Phlda2 does not appear to follow the straightforward rules
applied to a substantial number of imprinted genes whereby pa-
ternally expressed genes promote placental and foetal growth
whereas maternally expressed genes restrain placental and foetal
growth. Phlda2 resides within a complex imprinted domain
spanning several maternally expressed genes including Cdkn1c, a
potent embryonic growth restriction gene (Andrews et al., 2007;
Tunster et al., 2011). Neither loss-of-function of Phlda2 nor loss-of-
function of Cdkn1c alone in mice results in the increase in birth
weight predicted by the genomic conﬂict theory. It may be that
loss of function of such critically important genes has too severe an
impact on foetal development. Alternatively, the combined al-
teration may be required to generate larger offspring. Our data
from mouse models would predict an increase in foetal weight,
due to reduced Cdkn1c expression, alongside an increase in the
signalling function of the placenta, due to reduced Phlda2 ex-
pression, thus retaining the balance between foetal growth and
placental demands on maternal resources. Co-imprinting of these
two genes, which occurred after marsupials diverged for Eutherian
mammals (Suzuki et al., 2005, 2011), may consequently have
played an important role in the evolution of modern day mammals
that give birth to relatively mature offspring.
In conclusion, we have shown that Phlda2 modulates the sig-
nalling function of the placenta to limit the accumulation of pla-
cental glycogen and placental growth. While this does not provide
a facile explanation for paternal silencing of Phlda2, our work
highlights the complex relationship between the mother, the
foetus and the placenta whose requirements must be carefully
balanced for an optimal reproductive success.Competing interests statement
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